Review
Copyright ©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Pediatr. Nov 8, 2015; 4(4): 94-105
Published online Nov 8, 2015. doi: 10.5409/wjcp.v4.i4.94
Current management of pediatric soft tissue sarcomas
Surasak Sangkhathat
Surasak Sangkhathat, Department of Surgery and Tumor Biology Research Unit, Faculty of Medicine, Prince of Songkla University, Songkhla 90110, Thailand
Author contributions: Sangkhathat S reviewed and composed the manuscript.
Supported by The Anandamahidol Foundation.
Conflict-of-interest statement: None declared.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Surasak Sangkhathat, MD, PhD, Department of Surgery and Tumor Biology Research Unit, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla 90110, Thailand. surasak.sa@psu.ac.th
Telephone: +66-74-451401 Fax: +66-74-429384
Received: May 29, 2015
Peer-review started: June 2, 2015
First decision: July 3, 2015
Revised: July 21, 2015
Accepted: September 29, 2015
Article in press: September 30, 2015
Published online: November 8, 2015
Processing time: 165 Days and 9.5 Hours
Core Tip

Core tip: The manuscript describes current management of pediatric soft tissue sarcomas, a large group of rare tumors in pediatric age group. The group has two main categories; rhabdomyosarcoma (RMS) and non-RMS pediatric soft tissue tumors. Treatment of these tumors is in multidisciplinary fashion comprising of surgery, chemotherapy and radiation therapy. Decision making in management protocol for each patient is based on the risk determined by various clinical and pathological parameters. For cases with low-risk, surgical removal is usually adequate when adjuvant chemoradiation are proven helpful in cases with significant risk of recurrence. The overall survival in these tumors has become brighter in the recent decades.